JPS5188940A - - Google Patents

Info

Publication number
JPS5188940A
JPS5188940A JP50153194A JP15319475A JPS5188940A JP S5188940 A JPS5188940 A JP S5188940A JP 50153194 A JP50153194 A JP 50153194A JP 15319475 A JP15319475 A JP 15319475A JP S5188940 A JPS5188940 A JP S5188940A
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP50153194A
Other languages
Japanese (ja)
Other versions
JPS5324064B2 (OSRAM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5934284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS5188940(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of JPS5188940A publication Critical patent/JPS5188940A/ja
Publication of JPS5324064B2 publication Critical patent/JPS5324064B2/ja
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP15319475A 1974-12-21 1975-12-22 Expired JPS5324064B2 (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2460891A DE2460891C2 (de) 1974-12-21 1974-12-21 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
JPS5188940A true JPS5188940A (OSRAM) 1976-08-04
JPS5324064B2 JPS5324064B2 (OSRAM) 1978-07-18

Family

ID=5934284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP15319475A Expired JPS5324064B2 (OSRAM) 1974-12-21 1975-12-22

Country Status (16)

Country Link
US (1) US4024175A (OSRAM)
JP (1) JPS5324064B2 (OSRAM)
AT (1) AT340892B (OSRAM)
BE (1) BE836835A (OSRAM)
CA (1) CA1052811A (OSRAM)
CH (3) CH612665A5 (OSRAM)
DE (1) DE2460891C2 (OSRAM)
DK (1) DK147706C (OSRAM)
ES (1) ES443723A1 (OSRAM)
FI (1) FI62282C (OSRAM)
FR (1) FR2294697A1 (OSRAM)
GB (1) GB1465229A (OSRAM)
IE (1) IE42382B1 (OSRAM)
LU (1) LU74058A1 (OSRAM)
NL (1) NL181006C (OSRAM)
SE (1) SE423385B (OSRAM)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508362A (ja) * 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）、その製造および神経学的疾患の治療におけるその使用
JP2007510695A (ja) * 2003-11-11 2007-04-26 ザンボン　グループ　エス．ピー．エー． ガバペンチンの調製方法
KR100926921B1 (ko) * 2001-06-11 2009-11-17 제노포트 인코포레이티드 Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도
JP2009542617A (ja) * 2006-06-30 2009-12-03 ザック システム エス．ピー．エー． ガバペンチンの調製プロセス
WO2012015027A1 (ja) 2010-07-30 2012-02-02 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
WO2012018095A1 (ja) * 2010-08-06 2012-02-09 杏林製薬株式会社 ビシクロ［２．２．２］オクチルアミン誘導体またはその塩の製造方法
JPWO2021079887A1 (OSRAM) * 2019-10-25 2021-04-29

Families Citing this family (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
JPS5776189U (OSRAM) * 1980-10-28 1982-05-11
JPS6152583U (OSRAM) * 1984-09-11 1986-04-09
JPS61139881U (OSRAM) * 1985-02-21 1986-08-29
US4876279A (en) * 1986-05-05 1989-10-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
AU633612B2 (en) * 1989-08-25 1993-02-04 Warner-Lambert Company Improved process for cyclic amino acid anticonvulsant compounds
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
DE3928182A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
US5260467A (en) * 1989-11-16 1993-11-09 Pfizer Inc. Glutaric acid derivatives and preparation thereof
US5157138A (en) * 1989-11-16 1992-10-20 Pfizer, Inc. Glutaric acid derivatives and preparation thereof
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
FI905584L (fi) * 1989-11-16 1991-05-17 Lonza Ag Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra.
GB8925933D0 (en) * 1989-11-16 1990-01-04 Pfizer Ltd Glutaric acid derivatives and preparation thereof
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
ATE218135T1 (de) * 1996-02-07 2002-06-15 Warner Lambert Co Zyklischaminosäure als pharmazeutische mittel
ATE207878T1 (de) * 1996-03-14 2001-11-15 Warner Lambert Co Zyklische aminosäure als pharmazeutische wirkstoffe
BR9708180A (pt) * 1996-03-14 1999-07-27 Warner Lambert Co Amoniácidos cíclicos em pontes como agentes farmacêuticos
CA2255652C (en) 1996-07-24 2004-07-13 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
JP2002514187A (ja) * 1996-10-23 2002-05-14 ワーナー―ランバート・コンパニー 薬剤としての置換γ―アミノ酪酸
US6255526B1 (en) 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
WO1999008667A2 (en) 1997-08-19 1999-02-25 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
BR9812162A (pt) * 1997-09-08 2000-07-18 Warner Lambert Co Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
AU9318398A (en) 1997-10-07 1999-04-27 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
CA2303244C (en) * 1997-10-27 2005-12-06 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
US6984659B2 (en) * 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
HUP0100472A3 (en) 1997-12-16 2003-03-28 Warner Lambert Co Novel amines as pharmaceutical agents
JP2002508352A (ja) 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー ４（３）置換−４（３）−アミノメチル−（チオ）ピラン又はピペリジン誘導体（＝ガバペンチン類似体）、それらの製法および神経病理学的疾患の治療における使用
WO1999037296A1 (en) * 1998-01-23 1999-07-29 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
KR100669280B1 (ko) * 1998-05-15 2007-01-17 워너-램버트 캄파니 엘엘씨 감마-아미노부티르산 유도체 포함 고상 조성물 및 그의제조 방법
DE69918977T2 (de) 1998-05-15 2005-07-28 Warner-Lambert Co. Llc Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
ES2137137B1 (es) * 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
JP2002516312A (ja) 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
ITMI981535A1 (it) * 1998-07-03 2000-01-03 Zambon Spa Processo per la preparazione di gabapentina
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
JP2002541215A (ja) * 1999-04-09 2002-12-03 ユーロ−セルティック エス． ア． ナトリウムチャネル遮断薬組成物およびその使用
CA2371089A1 (en) * 1999-05-28 2000-12-07 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
US6710190B1 (en) 1999-05-28 2004-03-23 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
GEP20074142B (en) * 1999-06-10 2007-07-10 Warner Lambert Co Mono- and Disubstituted 3-Propyl Gamma-Aminobutyric Acids
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
DE60101476T2 (de) 2000-06-16 2004-05-27 Teva Pharmaceutical Industries Ltd. Stabiles gabapentin, das mehr als 20 ppm chlor enthält
SK302003A3 (en) * 2000-06-16 2003-07-01 Teva Pharma Stable gabapentin having pH within a controlled range
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
KR100785182B1 (ko) * 2000-06-26 2007-12-11 워너-램버트 캄파니 엘엘씨 수면 장애를 위한 가바펜틴 유사체
GB2364049A (en) * 2000-06-28 2002-01-16 Warner Lambert Co Cyclic ketones and their use in the synthesis of amino acids
DE50108104D1 (de) * 2000-09-14 2005-12-22 Gruenenthal Gmbh Beta-thio-aminosäuren
US6900192B2 (en) * 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US6992076B2 (en) * 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
IT1319234B1 (it) * 2000-10-23 2003-09-26 Zambon Spa Processo di preparazione di gabapentina.
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
HRP20030443A2 (en) 2000-11-02 2005-04-30 Teva Pharmaceutical Industries Ltd. Improved process for production of gabapentin intermediate
HRP20030420A2 (en) * 2000-11-30 2004-08-31 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors
PL365378A1 (en) * 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
JP2004524339A (ja) * 2001-03-16 2004-08-12 ソルケム イタリアーナ エス．ピー．エイ． 環状アミノ酸の調製方法
ITMI20011132A1 (it) 2001-05-29 2002-11-29 Procos Spa Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7420002B2 (en) * 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
IL144066A0 (en) * 2001-06-28 2002-04-21 Bromine Compounds Ltd Process for the preparation of 1,1-cyclohexane diacetic monoamide
ITMI20011772A1 (it) 2001-08-10 2003-02-10 A M S A Anonima Materie Sint E Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
EP1423168B1 (en) * 2001-09-03 2006-02-08 Newron Pharmaceuticals S.p.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
US6800782B2 (en) * 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
PL371944A1 (en) * 2002-01-31 2005-07-11 Warner-Lambert Company Llc Alpha 2 delta ligands to treat tinnitus
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
US20040034248A1 (en) * 2002-04-16 2004-02-19 Taro Pharmaceutical Industries, Ltd. Process for preparing gabapentin
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US7183259B2 (en) * 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
PL375090A1 (en) * 2002-06-27 2005-11-14 Warner-Lambert Company Llc Method of treating attention deficit hyperactivity disorder
CA2395931A1 (en) * 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
US7053122B2 (en) * 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092591A1 (en) * 2002-08-15 2004-05-13 Blakemore David Clive Therapeutic use of fused bicyclic or tricyclic amino acids
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US20040092498A1 (en) * 2002-08-16 2004-05-13 David Blakemore Substituted glycine derivatives for use as medicaments
ITMI20022071A1 (it) * 2002-10-01 2004-04-02 Erregierre Spa Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
EP1727784B1 (en) * 2002-11-18 2008-12-24 Nicholas Piramal India Limited Improved process for preparation of gabapentin
AU2002356427A1 (en) * 2002-11-20 2004-06-15 Sivaramakrishnan Hariharan An improved process for the preparation of gabalactam
AU2003297909A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
NZ540336A (en) * 2002-12-13 2008-03-28 Warner Lambert Co Gabapentin analogues for fibromyalgia and other related disorders
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP2172197A1 (en) * 2002-12-13 2010-04-07 Warner-Lambert Company LLC Octanoic acid derivative to treat fibromyalgia and other pains
KR20050085563A (ko) 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
WO2004054565A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders
GB0301143D0 (en) * 2003-01-17 2003-02-19 Amedis Pharm Ltd Compounds and their use
KR100743800B1 (ko) * 2003-01-22 2007-07-30 워너-램버트 캄파니 엘엘씨 사이클로프로필 베타-아미노산 유도체
WO2004078734A1 (en) * 2003-03-07 2004-09-16 Warner-Lambert Company Llc TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
WO2004093827A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in solid dosage forms and methods of use
WO2004093866A1 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Process for preparing phenolic acid salts of gabapentin
WO2004093867A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
MXPA05010515A (es) * 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
ITMI20030825A1 (it) * 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione di gabapentin esente da
US7439387B2 (en) * 2003-04-21 2008-10-21 Matrix Laboratories Ltd. Process for the preparation of Gabapentin form-II
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
JP2006527595A (ja) * 2003-06-19 2006-12-07 ファイザー・プロダクツ・インク １−シアノシクロヘキサンアセティックアシッドの生体触媒による調製
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
AU2004272111A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
AU2004271796A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders
JP5107576B2 (ja) * 2003-09-17 2012-12-26 ゼノポート，インコーポレイティド Ｇａｂａ類似体のプロドラッグを使用する不穏下肢症候群の治療または予防
DK1677767T3 (da) * 2003-10-14 2011-10-24 Xenoport Inc Krystallinsk form af gamma-aminobutyrsyre-analog
AU2004305563C1 (en) 2003-12-11 2011-07-07 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
WO2005087709A1 (en) * 2004-03-17 2005-09-22 Hikal Limited 4-t-butylgabapentin and its synthesis
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
JP2008501778A (ja) * 2004-06-09 2008-01-24 ファイザー・インク 疼痛の治療のためのレボキセチンの使用
GB0416228D0 (en) * 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0419849D0 (en) * 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
PL1809271T3 (pl) * 2004-09-10 2010-10-29 Newron Pharm Spa Zastosowania (R)-(halobenzyloksy)benzyloamino-propanamidów jako modulator kanałów sodowych i/lub wapniowych
AU2005301970B2 (en) 2004-11-04 2011-06-02 Arbor Pharmaceuticals, Llc Gabapentin prodrug sustained release oral dosage forms
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006302659A1 (en) * 2005-09-23 2007-04-19 Janssen Pharmaceutica, N.V. Hexahydro cyclooctyl pyrazole cannabinoid modulators
BRPI0616402A2 (pt) * 2005-09-23 2011-06-21 Janssen Pharmaceutica Nv moduladores de canabinóide de hexaidro-cicloeptapirazol
WO2007035945A1 (en) 2005-09-23 2007-03-29 Janssen Pharmaceutica, N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP1979593B1 (en) * 2006-02-03 2017-12-06 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
WO2007095513A1 (en) * 2006-02-14 2007-08-23 Janssen Pharmaceutica, Nv Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
AU2007222112A1 (en) * 2006-03-06 2007-09-13 Pfizer Products Inc. Alpha-2-delta ligands for non-restorative sleep
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7442834B2 (en) * 2006-06-12 2008-10-28 Zhejiang Chiral Medicine Chemicals Co., Ltd. Process suitable for industrial scale production of gabapentin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009006080A (es) * 2006-12-08 2009-07-14 Xenoport Inc Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
PL2125021T3 (pl) 2006-12-22 2011-10-31 Recordati Ireland Ltd Leczenie skojarzone zaburzeń w obrębie dolnych dróg moczowych z zastosowaniem ligandów α2δ i przeciwzapalnych leków niesterydowych (NSAIDs)
BRPI0808962A2 (pt) * 2007-03-15 2014-08-26 Sun Pharma Advanced Res Co Ltd Agente para drogas
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090062392A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched gabapentin
WO2009061934A1 (en) * 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
CA2706575C (en) * 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
CA2740087C (en) * 2008-10-08 2019-07-23 Kyphia Pharmaceuticals, Inc. Gaba conjugates and methods of use thereof
EP2400989B1 (en) 2009-02-24 2016-08-10 Nektar Therapeutics Gabapentin-peg conjugates
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2368872A1 (en) 2010-03-25 2011-09-28 Serichim S.r.l. Process for the preparation of Gabapentin
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
US20130078290A1 (en) 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
US8431739B2 (en) 2010-06-14 2013-04-30 Divi's Laboratories, Ltd. Process for the preparation of gabapentin
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
ITMI20131757A1 (it) 2013-10-22 2015-04-23 Zach System Spa Processo di preparazione di gabapentina
CA2928559C (en) 2013-11-01 2022-08-30 Glytech, Inc. Method of manufacturing d- or l-form amino acid derivative possessing a thiol group
TN2016000228A1 (en) 2013-12-17 2017-10-06 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS.
JP2017503765A (ja) 2013-12-17 2017-02-02 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ガバペンチノイドおよびシグマ受容体の組み合わせ
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
MX384760B (es) 2018-07-04 2025-03-14 Federico Amezcua Amezcua Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
US10399926B1 (en) 2018-08-01 2019-09-03 Divi's Laboratories Ltd. Process for the preparation of gabapentin
CN120168489A (zh) 2018-10-11 2025-06-20 萨尼菲特治疗有限公司 用于治疗异位钙化的肌醇磷酸酯类
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
GB2625579A (en) 2022-12-21 2024-06-26 Novumgen Ltd An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508362A (ja) * 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）、その製造および神経学的疾患の治療におけるその使用
KR100926921B1 (ko) * 2001-06-11 2009-11-17 제노포트 인코포레이티드 Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도
JP2007510695A (ja) * 2003-11-11 2007-04-26 ザンボン　グループ　エス．ピー．エー． ガバペンチンの調製方法
JP2009542617A (ja) * 2006-06-30 2009-12-03 ザック システム エス．ピー．エー． ガバペンチンの調製プロセス
WO2012015027A1 (ja) 2010-07-30 2012-02-02 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
US8946267B2 (en) 2010-07-30 2015-02-03 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
US9226924B2 (en) 2010-07-30 2016-01-05 Toray Industries, Inc. Methods of treating or preventing neuropathic pain
WO2012018095A1 (ja) * 2010-08-06 2012-02-09 杏林製薬株式会社 ビシクロ［２．２．２］オクチルアミン誘導体またはその塩の製造方法
JPWO2021079887A1 (OSRAM) * 2019-10-25 2021-04-29
WO2021079887A1 (ja) 2019-10-25 2021-04-29 国立大学法人京都大学 タウオパチーの予防又は治療剤

Also Published As

Publication number Publication date
AU8774175A (en) 1977-06-23
JPS5324064B2 (OSRAM) 1978-07-18
BE836835A (fr) 1976-06-18
FI62282B (fi) 1982-08-31
AT340892B (de) 1978-01-10
NL7514900A (nl) 1976-06-23
DK581475A (da) 1976-01-22
FR2294697A1 (fr) 1976-07-16
SE423385B (sv) 1982-05-03
IE42382B1 (en) 1980-07-30
ATA975075A (de) 1977-05-15
FI753613A7 (OSRAM) 1976-06-22
CH612665A5 (OSRAM) 1979-08-15
CH612666A5 (OSRAM) 1979-08-15
DK147706B (da) 1984-11-19
FR2294697B1 (OSRAM) 1978-07-28
US4024175A (en) 1977-05-17
DK147706C (da) 1985-05-13
DE2460891C2 (de) 1982-09-23
NL181006B (nl) 1987-01-02
NL181006C (nl) 1987-06-01
FI62282C (fi) 1982-12-10
CH612664A5 (OSRAM) 1979-08-15
LU74058A1 (OSRAM) 1976-07-20
IE42382L (en) 1976-06-21
GB1465229A (en) 1977-02-23
SE7514442L (sv) 1976-06-22
CA1052811A (en) 1979-04-17
ES443723A1 (es) 1977-04-16
DE2460891A1 (de) 1976-07-01

Similar Documents

Publication Publication Date Title
AU474179B2 (OSRAM)
AU495898B2 (OSRAM)
AU496555B2 (OSRAM)
AU471463B2 (OSRAM)
AU7099174A (OSRAM)
AU6717074A (OSRAM)
AR198999Q (OSRAM)
BG19564A1 (OSRAM)
BG19932A1 (OSRAM)
AU480308A (OSRAM)
AU480659A (OSRAM)
AU480660A (OSRAM)
AU480764A (OSRAM)
AU480783A (OSRAM)
AU480922A (OSRAM)
AU481065A (OSRAM)
AU481119A (OSRAM)
AU479777A (OSRAM)
AU481301A (OSRAM)
AU481340A (OSRAM)
AU482286A (OSRAM)
BE525532A (OSRAM)
BE829575A (OSRAM)
BE836685A (OSRAM)
BG20519A1 (OSRAM)